Back
For best output, select "Paper Size" as "A4" and "Margin" as "0" or "None".
To save or print to PDF, please select Print Destination > Save as PDF, enable Background Graphics under "More Settings", then click "Save".
During the congress, E-Posters will be accessible to all participants on the congress website 24/7, as well as in the E-poster stations in the congress center.
Preparing your E-Poster
Please review the E-Poster format requirements carefully when preparing your E-Poster. Should your E-Poster not meet the mentioned requirements, it may not be displayed as described above.
E-Poster Submission Deadline
Please prepare and upload your E-Poster no later than March 14, 2026 11.59PM CET. After this date, you will no longer be able to prepare and upload your E-poster and it will not be displayed and accessible on the congress website.
Please follow the instructions below to input your abstract title.
Abstract titles should be brief and reflect the content of the abstract.
Objective: IgA nephropathy is one of the most common primary glomerular diseases in China. Its main pathological feature is the deposition of IgA in the glomerular mesangial area. Clinically, it often presents with proteinuria, hematuria, and progressive decline in renal function. Currently, there are no specific treatment methods. Traditional immunosuppressive therapies have limited efficacy and significant side effects. In recent years, the dual-target drug Telitacicept, which targets B-cell activation factor (BLyS) and proliferation-inducing ligand (APRIL), has provided a new direction for the treatment of IgA nephropathy. This study aims to evaluate the clinical efficacy and safety of the dual-target drug Telitacicept, which targets B-cell growth factors APRIL and BLyS, in the treatment of IgA nephropathy.
Method: All patients received Telitacicept treatment, with doses adjusted according to their clinical condition, and were followed up for 6–28 months (Table 1). The efficacy and safety of the treatment were evaluated by comparing pre- and post-treatment indicators, including 24-hour urinary protein quantification, urine protein-to-creatinine ratio, serum creatinine, and eGFR.
Results: The results showed that all patients experienced a significant reduction in proteinuria levels during the treatment period. The majority of patients exhibited a reduction of over 50% in 24-hour urinary protein quantification from baseline. Meanwhile, eGFR remained stable or showed a slight increase, suggesting renal function was preserved (Table 2). Particularly noteworthy is the case of one patient who completed 28 months of follow-up. The indicator changes at multiple time points in this patient further confirmed that continuous medication can maintain efficacy, while discontinuation may lead to a rebound in indicators. This highlights the need for individualized adjustment of the treatment regimen to sustain long-term efficacy (Table 2). Throughout the entire treatment period, no infections, liver function abnormalities, or other serious adverse events were observed, indicating the drug was well-tolerated with a favorable safety profile.
Conclusion: As a novel biologic agent, Telitacicept simultaneously targets BLyS and APRIL, thereby suppressing abnormal immune responses at their source. This action reduces the formation and deposition of IgA immune complexes, subsequently alleviating renal tissue damage. Although this study has a limited sample size, the results consistently demonstrate that Telitacicept effectively reduces proteinuria, delays the progression of renal dysfunction, and exhibits a favorable tolerability profile. In summary, Telitacicept shows promising efficacy and safety in the treatment of IgA nephropathy. Future larger-scale, multicenter, randomized controlled trials are warranted to further validate its long-term benefits and determine the optimal treatment strategy.
